Please assess the completion status of the following clinical trial:

Trial Title: A 6-Month Extension Study of OTO-104 in Meniere's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria includes, but is not limited to:~* Subject has completed the OTO-104 Phase 2b (104-201102) or Phase 3 (104-201506) clinical study.~* Subject has a diagnosis of definite unilateral Meniere's disease by 1995 AAO-HNS criteria~Exclusion Criteria includes, but is not limited to:~* Subject is pregnant or lactating.~* Subject has a history of immunodeficiency disease.~* Subject has experienced an adverse reaction to intratympanic injection of steroids.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OTO-104 (Type: EXPERIMENTAL): 12 mg dexamethasone

Based on this trial design, predict the completion outcome and termination type (if applicable).